Nov. 7 (Bloomberg) — New Jersey
voters rejected a $450 million bond measure to fund stem-cell research,
a defeat for Democratic Governor Jon Corzine, who backed the proposal
with his own money and advocated on its behalf.
With 95 percent of precincts reporting, the question was defeated by 53
percent to 47 percent, according to nj.com, a Web site affiliated with
the Star-Ledger of Newark. The measure would have authorized the state
to borrow as much as $45 million annually for 10 years to fund
scientists’ work in the field.
The rejection shows voters didn’t buy Corzine’s arguments that
borrowing for investment in stem-cell research would attract economic
development and help retain business in New Jersey, home to more
pharmaceutical companies than any other in the U.S. state, said Ingrid
Reed, a political scientist at Rutgers University. The governor
personally donated $150,000 to a stem-cell advocacy group campaigning
for the measure.
“This was clearly a big defeat,” said Reed, director of Rutgers’
Eagleton Project New Jersey in New Brunswick. Voters “didn’t have
confidence that this would pay off in the short run,” she said.
This is certainly good news that even in
New Jersey the Pied Piper hymn of “cures, cures, cures” doesn’t always
work. It would be nice to think that the total disingenuous
of ESCR supporters with their empty promises and texts of the bill that
once again tried to fool voters in concern to cloning is what did the
bill in. Most news outlets are reporting this as a case of
cost-conscious voters rejecting it for monetary reasons.
Surely some did it on those grounds, but if the ESCR hype was
being bought this surely would not have hindered it.